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Summary
Objective:  Quality  of  life  (QoL)  is  now  as  much  an  assessment  criterion  in  clinical  trials  in  head
and neck  oncology  as  are  survival  and  response  rate.  It  is  therefore  important  to  be  able  to
choose an  adapted  tool  from  the  wide  range  of  QoL  instruments  available.  The  present  study
presents an  inventory  of  QoL  scales  validated  in  their  French-language  version,  to  facilitate  the
selection of  appropriate  tools  showing  good  psychometric  properties.
Materials  and  methods:  QoL  scales  cited  in  all  492  French  and  English  language  articles  pub-
lished between  March  1st,  2006  and  April  3rd,  2012,  referenced  on  Medline  and  retrieved  using
the keywords  ‘‘quality  of  life’’  AND  ‘‘head  and  neck’’  AND  ‘‘cancer’’,  were  inventoried  and
classiﬁed thematically  in  a  search  of  the  literature.
Results:  Ninety  QoL  scales  are  presented  by  theme  (ORL  oncology,  voice,  swallowing  and  mas-
tication,  mucosities  and  xerostomia,  etc.),  specifying  psychometric  quality  and  citation  level.
Conclusion:  The  present  report  constitutes  a  guide  to  selecting  QoL  tools  adapted  to  head  and
neck oncology  studies.
©  2013  Elsevier  Masson  SAS.  All  rights  reserved.
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iIntroduction
In  1994,  the  World  Health  Organization  (WHO)  deﬁned  qual-
ity  of  life  (QoL)  as  ‘‘individuals’  perception  of  their  position
in  life  in  the  context  of  the  culture  and  value  systems  in
which  they  live  and  in  relation  to  their  goals,  expecta-
tions,  standards  and  concerns.  It  is  a  broad  ranging  concept
affected  in  a  complex  way  by  the  person’s  physical  health,
psychological  state,  level  of  independence,  social  relation-
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http://dx.doi.org/10.1016/j.anorl.2013.05.002hips,  personal  beliefs  and  their  relationship  to  salient
eatures  of  their  environment’’  [1]. It  concerns  not  only
hysical,  psychological  and  social  well-being  and  functional
ndependence  but  also  self-fulﬁlment,  spiritual  life,  sexual-
ty  and  ﬁnance  [2].
Ultimately,  however  it  may  be  deﬁned  in  medical  terms,
oL  is  a  subjective  parameter  representing  the  individual’s
erception  of  him-  or  herself  in  the  world  (social  self).
In  oncology,  QoL  is  a  function  of  health  status  and
he  concept  has  evolved  over  the  years.  Cure  in  terms  of
‘quantity  of  life’’  was  long  the  oncologist’s  main  preoc-
upation  and  survival  the  prime  assessment  criterion.  The
‘quality  of  life’’  criterion  developed  due  on  the  one  hand
o  patients’  limited  life  expectancy  with  ‘‘cure’’  as  a  rare
served.
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herapeutic  endpoint,  but  also,  on  the  other  hand,  to  pro-
onged  survival  thanks  to  advances  in  treatment  and  family
nvolvement.  QoL  has  now  become  a  factor  in  the  assess-
ent  criteria  of  clinical  trials,  on  a  par  with  survival  and
esponse  rate  [4,5].
Taking  QoL  into  account  in  head  and  neck  oncology  is
o  longer  a  matter  of  debate.  Patients  are  confronted  by
 highly  lethal  pathology  and  moreover  need  to  learn  to
eal  with  the  impact  of  both  disease  and  treatment  on  their
hysical  appearance,  on  functions  as  basic  as  swallowing,
reathing  and  speaking  [6,7]  and  also  on  their  everyday
ife.  They  are  frequently  disadvantaged  and  of  low  socio-
conomic  status,  with  their  social  network  impaired  by  the
mpossibility  of  working  [8].  Their  physical  disorders  and  the
sychological  results  of  damaging  treatment  lead  to  solitude
nd  self-isolation,  undermining  quality  of  life  [9].
The  following  sections  list  the  QoL  assessment  instru-
ents  available  to  head  and  neck  oncology,  detailing  their
requency  of  use,  means  of  implementation  and  suitability.
uantitative assessment
he  objective  is  to  enable  tools  to  be  selected  and  adapted
o  assessment  criteria  while  adhering  to  their  speciﬁc
nstructions  for  use,  as  they  can  neither  be  altered  nor
mplemented  only  partially.
QoL  assessment  involves  choosing  a  tool  from  the  many
vailable.  In  2003,  McHorney  [10]  cited  more  than  75  scales
or  use  in  oncology.  The  choice  of  tool  is  fundamental  to
tudy  design  and  should  be  made  according  to  the  study
bjective,  target  population  characteristics  (head  and  neck
ancer  patients)  and  the  psychometric  properties  of  the
cale.
Quality  of  life  is  a  multidimensional  subjective  parame-
er,  requiring  a  scale  covering  a  wide  range  of  items  in  a
ariety  of  ﬁelds  (physical,  cognitive,  etc.).
The  EORTC  QLQ-C30,  for  example,  comprises
0  questions  in  all,  with  24  questions  assessing  1  global
ealth  scale,  5 functional  scales  (physical,  role,  cognitive,
ocial  and  emotional)  and  3  symptom  scales  (nausea,  pain
nd  fatigue)  and  6  questions  for  6  simple  items  (dyspnea,
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t
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Table  1  Generic  scales.
Scale  Nature  
Short  Form-36
(SF-36)
Validated  generic  scale
http://www.sf-36.org/
Short Form-12
(SF-12)
Validated  generic  scale
http://www.sf-36.org/
EuroQol EQ-5D  Validated  generic  scale
http://www.euroqol.org/
Patient Generated  Index  (PGI)  Validated  disease-  or
treatment-speciﬁc  scale  [15]N.  Heutte  et  al.
nsomnia,  loss  of  appetite,  constipation,  diarrhea  and
nancial  impact).
The  various  QoL  scales  can  be  divided  into  2  groups:
eneric  and  speciﬁc.  Generic  scales  (EuroQol,  SF-36,  PGI,
tc.)  address  quality  of  life  and  health  status  indepen-
ently  of  any  pathology  in  particular,  enabling  comparison
etween  patients  with  different  pathologies  or  with
ealthy  controls.  Speciﬁc  scales  address  a  given  disease
EORTC  QLQ-C30  for  cancer,  Fact-H&N  for  head  and  neck
ancer,  etc.),  a  given  ﬁeld  and/or  symptom  (fatigue,
epression,  xerostomia,  dysphagia,  etc.)  or  a given  treat-
ent  modality  (surgery  or  radiation  therapy),  making
hem  more  sensitive  to  clinical  variations  and  treatment
ffects.
Self-administered  questionnaires  are  more  sensitive  than
hose  ﬁlled  out  by  the  physician  or  family  [11]. They  need
o  be  ‘‘acceptable’’  to  the  study  population  so  as  to  maxi-
ize  response  rates  and  the  number  of  items  answered  (and
ence  the  number  of  domains  assessed).  They  should  be  as
uick  to  ﬁll  out  as  possible.
To  qualify  as  ‘‘validated’’,  a  scale  has  to  meet  a  certain
umber  of  criteria  [12]:
 validity:  ability  to  measure  what  it  claims  to  measure;
 reliability:  stability  or  reproductibility  over  time  in  a  pop-
ulation  with  unchanged  health  status  or  quality  of  life;
 sensitivity:  ability  to  detect  change  over  time,  especially
at  both  extreme  ranges  (no  ceiling  or  ﬂoor  effect).
Psychometric  validation  involves  statistical  analysis.
When  a  validated  scale  is  altered  in  terms  of  content  or
resentation  or  translated  into  another  language,  comple-
entary  validation  is  required,  to  ensure  validity  [13].  Any
dditional  questions  should  be  appended  to  the  end  of  the
uestionnaire,  so  as  not  to  ‘‘break’’  its  structure  [14].
Tables  1—21  present  the  scales  referred  to  in  the  492  arti-
les  published  between  March  1st,  2006  and  April  3rd,  2012,
eferenced  on  Medline  and  retrieved  using  the  key-words
‘quality  of  life’’  AND  ‘‘head  and  neck’’  AND  ‘‘cancer’’,  with
he  following  limits:  Humans,  English,  French,  Publication
ield:  Title/Abstract.  The  scales  that  have  been  validated
Citations  Misc.
21  8  dimensions:  physical  functioning,  role
limitations  (physical  problems),  bodily  pain,
general  health,  vitality,  social  functioning,
role  limitations  (emotional  problems),  and
mental  health.
6  Abridged  version  of  Short  Form-36,  covering
the same  dimensions
3  5  dimensions:  mobility,  self-care,  usual
activities,  pain/discomfort  and
anxiety/depression
1  1  measure  of  global  quality  of  life
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Table  2  Cancer-speciﬁc  scales.
Scale  Nature  Citations  Misc.
QLQ-C30  Validated  cancer-speciﬁc  scale
http://groups.eortc.be/qol/
>  50  8  dimensions:  physical,  role,  cognitive,
social,  emotional,  nausea,  pain,  fatigue
6 simple  items:  dyspnea,  insomnia,  loss  of
appetite,  constipation,  diarrhea  and
ﬁnancial  impact
1  global  QoL  scale
EORTC QLQ-C15-PAL Validated  scale  speciﬁc  to  QoL
in  advanced,  incurable,
symptomatic  cancer  with  a  few
months’  median  life
expectancy
http://groups.eortc.be/qol/
1  5  dimensions:  physical,  emotional,  nausea,
pain,  fatigue
4  simple  items:  dyspnea,  insomnia,  loss  of
appetite,  constipation
1  global  QoL  scale
Functional  Assessment  of
Cancer  Therapy  (Fact-G)
Validated  cancer-speciﬁc  scale
http://www.facit.org/
14  4  dimensions:  physical,  social/family,
emotional,  functional  well-being
Spitzer Quality  of  Life
Index  (SQLI)
Speciﬁc  to  cancer  and  chronic
disease,  not  validated  in
French  [17]
1  5  dimensions:  activity,  daily  living,  health,
support  of  family  and  friends,  and  outlook
Memorial Symptom
Assessment  Scale  (MSAS)
Speciﬁc  to  cancer,  not
validated  in  French  [18]
1  3  dimensions:  physical,  emotional  and
global  distress
1 global  score
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vin  French-language  versions  are  at  the  top  of  the  list  in  each
Table.  Otherwise,  scales  are  ranked  by  citation  rate.
Finally,  study  parameters  have  to  be  scored  according  to
the  design  of  the  scale  used,  which  should  therefore  prefer-
ably  accommodate  as  wide  a  range  of  scores  as  possible  in
the  proposed  target  population  of  the  study,  so  as  to  maxi-
mize  precision.
The  most  widely  used  generic  scales  are  the  SF-36  fol-
lowed  by  the  SF-12  (Table  1).  Administration  time  for  the
SF-36  is  10  minutes  [16].  Normal  values  are  available  on  the
website  shown  in  Table  1  below.
The  main  cancer-speciﬁc  scales  available  in  validated
French-language  versions  are  the  QLQ-C30  and  Fact-G
(Table  2).  Administration  times  are  respectively  11  and
5  minutes  [19].
The  main  scales  speciﬁc  to  head  and  neck  cancer  and
available  in  validated  French-language  versions  are  the  QLQ-
H&N35,  Fact-H&N  and  UW-QOL  (Table  3).  Administration
times  are  respectively  11,  5  and  5  minutes  [19].  The  EORTC
QLQ-H&N35  scale  is  currently  under  revision  to  improve  its
management  of  side-effects  related  to  surgery  and  radiation
therapy  (severe  mucositis,  hair-loss,  neuropathy,  chronic
dysphagia,  etc.).
Table  4  presents  scales  speciﬁc  to  other  forms  of  cancer.
The  one  scale  speciﬁc  to  care  with  a  validated
French  version  concerns  cancer  patients’  natural  caregivers
(Table  5).There  are  2  scales  speciﬁc  to  care  satisfaction,  both  with
validated  French  versions  (Table  6).
The  VHI  is  a  self-assessment  scale  measuring  the  sever-
ity  of  the  disability  entailed  by  voice  disorder  (Table  7).  It
i
ns  a validated  instrument,  easy  for  the  therapist  to  imple-
ent  and  for  the  patient  to  ﬁll  out:  it  takes  8  minutes,  and
an  thus  be  incorporated  in  a  vocal  assessment  session.  A
hort  version,  the  VHI-10,  has  been  validated  for  both  initial
ssessment  and  follow-up  of  dysphonia.
The  SHI  is  a  speech  assessment  scale  for  oral  or
ropharyngeal  cancer  patients.  Unlike  the  VHI,  it  assesses
honation  disorder  in  patients  in  whom  it  is  not  only  the
oice  that  is  affected.
The  V-RQOL  has  the  particularity  of  highlighting  quality
f  life  rather  than  disability.  It  can  be  implemented  in  all
ypes  of  dysphonia.
The  Voice  Prosthesis  Questionnaire  (VPQ)  is  a
peech  assessment  scale  for  patients  ﬁtted  with  a
racheo-esophageal  voice  valve  following  total  laryn-
ectomy.
The  SECEL  is  designed  to  assess  communication  disorder
ollowing  laryngectomy.  A  new  version,  the  S-SECEL,  is  also
dapted  to  communication  disorder  following  other  treat-
ents  for  laryngeal  cancer  (radio-chemotherapy).
The  VAPP  scale  is  based  on  the  World  Health  Organi-
ation’s  ICIDH  (International  Classiﬁcation  of  Impairments,
isabilities  and  Handicaps,  1997).  It  highlights  a distinction
etween  2  dimensions  of  voice  disorder:  limitation  of  activ-
ties  and  restricted  participation  in  these  activities;  this
istinction  had  not  previously  been  made  in  QoL  scales  for
ocal  disorder.The  VoiSS  is  a  sensitive  assessment  tool  for  dysphonia  and
ts  evolution.
The  VPQ  (Voice  Performance  Questionnaire)  was  origi-
ally  designed  for  self-assessment  of  vocal  performance  in
36  N.  Heutte  et  al.
Table  3  Scales  speciﬁc  to  head  and  neck  oncology.
Scale  Nature  Citations  Misc.
QLQ-H&N35  Validated  scale  speciﬁc  to  head  and
neck  oncology  (supplementary
module  to  QLQ-C30)
http://groups.eortc.be/qol/
>  50  7  dimensions:  pain,  swallowing,
taste/smell,  speech,  eating  in  public,
social  life,  sexuality
11  simple  items
Fact-H&N  Validated  scale  speciﬁc  to  head  and
neck  oncology
http://www.facit.org/
27  4  dimensions:  physical,  social/family,
emotional,  functional  well-being
12 simple  items  speciﬁc  to  head  and
neck  cancer
University  of  Washington
Questionnaire  (UW-QOL)
Validated  scale  speciﬁc  to  head  and
neck  oncology
http://depts.washington.edu/otoweb/
research/head  neck  cancer.htm
http://www.headandneckcancer.co.uk/
43  12  items:  pain,  appearance,  activity,
leisure,  swallowing,  mastication,
speech,  shoulder  dysfunction,  taste,
production  of  saliva,  mood,  anxiety
MD Anderson  Symptom
Inventory  -Head  and  Neck
(MDASI-HN)
Validated  scale  speciﬁc  to  head  and
neck  oncology
http://www3.mdanderson.org/depts/
symptomresearch/
2  3  dimensions:  level  of  general
associated  symptom  severity,  impact
of  symptom  severity  on  daily  life,
level  of  speciﬁc  head  and  neck
symptom  severity
Head and  Neck  Performance
Status  Scale  (PSS-HN)
Validated  scale  speciﬁc  to  head  and
neck  oncology  [20,21]
9  3  dimensions:  normality  of  feeding,
and  ability  to  speak  and  to  eat  in
public
University of  Michigan  Head
and  Neck  Speciﬁc  Quality  of
Life  Instrument  (HNQoL)
Scale  speciﬁc  to  head  and  neck
oncology,  not  validated  in  French  [22]
8  4  dimensions:  pain,  communication,
feeding  and  emotion
Head and  Neck  Cancer
Inventory  (HNCI)
Scale  speciﬁc  to  head  and  neck
oncology,  not  validated  in  French  [23]
10  4  dimensions:  eating,  speech,
esthetics,  and  social  disruption  (pain,
work,  etc.)
Auckland Quality  of  Life
Questionnaire  (AQLQ)
comprising  3  questionnaires:
Life  Satisfaction  Score,
General  Health
Questionnaire12  and
Functional  Ability
Scale  speciﬁc  to  head  and  neck,  not
validated  in  French  [24,25]
3  5  dimensions:  physical,  symptoms,
social,  psychological,  well-being
11 items  of  psychological  well-being
and  life  satisfaction
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atients  with  non-organic  dysphonia,  but  has  been  extended
o  studies  of  organic  dysphonia.
The  PHI  is  the  only  instrument  originally  designed  and
alidated  in  French;  it  is  based  on  the  Voice  Handicap  Index
VHI)  and  Deglutition  Handicap  Index  (DHI)  and  enables
elf-assessment  of  speech  and  communication  disability  in
ysarthria  patients.
No  scales  speciﬁc  to  mucosities  or  xerostomia  have  been
alidated  in  their  French-language  versions  (Table  8).  A  pre-
iminary  validation  phase  will  be  needed  for  them  to  be
mployed.
The  only  deglutition-speciﬁc  scales  with  validated
rench-language  versions  are  the  DHI  and  SWAL-QOL
m
p
i
iTable  9).  A  preliminary  validation  phase  is  needed  for  the
thers.
Neither  of  the  two  scales  speciﬁc  to  shoulder  function  has
een  validated  in  their  French-language  versions  (Table  10).
 preliminary  validation  phase  will  be  needed  for  them  to
e  employed.
The  only  scale  speciﬁc  to  dental  pathology  with  a  val-
dated  French-language  version  is  the  GOHAI  (Table  11),
hich  was  validated  in  a  general  population.  A  comple-
entary  module  of  the  QLQ-C30,  the  QLQ-OH17  [74],  is
resently  under  validation  in  various  translations,  includ-
ng  French,  assessing  the  QoL  impact  of  oral  and  dental
ssues.
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Table  4  Scales  speciﬁc  to  ‘‘other  cancers’’.
Scale  Nature  Citations  Misc.
Functional  Assessment  of
Cancer  Therapy
-Nasopharyngeal  (FACT-NP)
Speciﬁc  to  nasopharyngeal  cancer,
validated
http://www.facit.org/
1  4  dimensions:  physical,  social/family,
emotional,  and  functional  well-being
16 speciﬁc  items:  e.g.,  eating,
swallowing,  dry  mouth,  appetite,
taste,  voice  quality,  communication,
appearance,  pain,  neck  motion,
tinnitus,  hearing,  vision,  smell  and
nasal  obstruction
QLQ-OES18  Speciﬁc  to  esophageal  cancer
(supplementary  module  to  QLQ-C30),
validated
http://groups.eortc.be/qol/
1  18  items:  dysphagia,  feeding,  reﬂux,
chest/abdominal  pain.
Fact-E Speciﬁc  to  esophageal  cancer
http://www.facit.org/
1  4  dimensions:  physical,  social/family,
emotional  and  functional  well-being
17 simple  items  speciﬁc  to  feeding,
appetite,  swallowing,  dry  mouth,
nocturnal  cough,  voice,
communication,  pain,  weight  loss.
Table  5  Scales  speciﬁc  to  care  impact.
Scale  Nature  Citations  Misc.
Caregiver  Quality  of  Life  Index
- Cancer  (CQOLC)
Speciﬁc  to  care  impact,  validated
[26,27]
1  1  total  score  and  4  sub-scales:  burden
of  care,  disturbance,  positive
adaptation,  and  ﬁnancial  worry.
Head and  Neck  Radiotherapy
Questionnaire  (HNRQ)
Speciﬁc  to  head  and  neck  cancer,  not
validated  in  French  [28]
3  6  dimensions:  oral  cavity  (mouth),
throat,  skin,  digestive  function,
energy,  and  psychosocial.
Neck Dissection  Impairment
Index  (NDII)
Speciﬁc  to  treatment,  not  validated
in French  [29]
2  10  items  for  1  global  score
Quality of  Life  Radiation
Therapy  Instrument
(QOL-RTI/H&N)
Speciﬁc  to  treatment,  not  validated
in French  [30,31]
1  25  general  QoL  items
14  more  speciﬁc  head  and  neck  items
Quality of  Life  -  Enteral
Feeding  questionnaire
(QOL-EF)
Speciﬁc  to  impact  of  enteral  feeding
tubes  on  head  and  neck  cancer
patients,  not  validated  in  French  [32]
1  20  items
Table  6  Scales  speciﬁc  to  care  satisfaction.
Scale  Nature  Citations  Misc.
EORTC  SAT  32  (Satisfaction
with  care)
Speciﬁc  to  care  satisfaction,
validated
http://groups.eortc.be/qol/
1  32  items  on  perceived  care  quality
and  patient’s  relation  to  physicians
and  nurses  and  to  care  organization
and  hospital  organization  as  a  whole
OUT-PATSAT 35  Speciﬁc  to  ambulatory  care
satisfaction  (chemotherapy  and
radiotherapy),  validated  [33]
1  35  items  on  outpatient  satisfaction
with  physicians  and  care  staff  and
organization  of  care  and  departments
38  N.  Heutte  et  al.
Table  7  Scales  speciﬁc  to  voice  and  speech.
Scale  Nature  Citations  Misc.
Vocal  Handicap  Index
(VHI/VHI-10)
Speciﬁc  to  voice,  validated  for
30-item  version  [34,35],
not validated  in  French  for  10-item
version  [36,37]
10  3  dimensions:  functional,  physical
and  emotional  aspects  of  vocal
handicap
1 global  score
Speech Handicap  Index  (SHI)  Speciﬁc  to  speech,  validated  [38,39]  2  2  dimensions:  speech  and
psycho-social
2  isolated  items
1  global  score
University of  Michigan
Voice-Related  Quality  of  Life
(V-RQOL)
Speciﬁc  to  voice,  not  validated  in
French  [40]
3  2  dimensions:  social-emotional  and
physical
1 global  score
Voice Prosthesis  Questionnaire
(VPQ)
Speciﬁc  to  voice,  not  validated  in
French  [41]
1  45  items
Self Evaluation  of
Communication  Experiences
after  Laryngectomy
(SECEL/S-SECEL)
Speciﬁc  to  head  and  neck  cancer,  not
validated  in  French  [42,43]
1  3  dimensions:  general,  experience  of
voice,  attitude
1 global  score
Voice Activity  Participation
Proﬁle  (VAPP)
(speciﬁc  scale  not  retrieved
in literature  search)
Speciﬁc  to  voice,  not  validated  in
French  [44]
28  items  on:  severity,  social,
occupational  and
communication-related  impact,
emotional  impact
1 global  score
Voice symptom  scale  (VoiSS)
(speciﬁc  scale  not  retrieved
in literature  search)
Speciﬁc  to  voice,  not  validated  in
French  [45]
3  dimensions:  deﬁciency,  emotional
aspect,  physical  symptoms
Voice Performance
Questionnaire  (VPQ)
(speciﬁc  scale  not  retrieved
in literature  search)
Speciﬁc  to  voice,  not  validated  [46]  12  items:  physical  symptoms  and
socioeconomic  impact  of  vocal
disorder
1 global  score
Parole Handicap  Index  (PHI)
(speciﬁc  scale  not  retrieved
Speciﬁc  to  speech,  validated  in
French  [47]
3  dimensions:  physical,
communication,  and  social  handicap
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No  scales  speciﬁc  to  feeding  issues  have  been  validated
n  their  French-language  versions  (Table  12).  A  preliminary
alidation  phase  will  be  needed  for  them  to  be  employed.
Both  of  the  fatigue-speciﬁc  scales  cited  in  the  reports
ave  validated  French-language  versions  (Table  13).  Some
uestions  are  found  in  both  questionnaires.
A  complementary  module  of  the  QLQ-C30,  the  QLQ-FA13
77],  is  presently  under  validation  in  various  translations,
ncluding  French,  assessing  cancer-related  fatigue.
No  scales  speciﬁc  to  oral  pain  have  been  validated  in
heir  French-language  versions  (Table  14).  A  preliminary
alidation  phase  will  be  needed  for  them  to  be  employed.
Five  scales  speciﬁc  to  anxiety  and  depression  have  vali-
ated  French-language  versions  (Table  15).  The  most  widely
sed  is  the  HADS.  A  stress-speciﬁc  scale,  the  PSS,  comes  in validated  French-language  version.
A  scale  speciﬁc  to  sexuality  has  yet  to  be  validated  in  a
rench-language  version  (Table  16).  A  preliminary  validation
hase  will  be  needed  for  it  to  be  employed.  The  Derogatis
o
t
e
tGlobal  score
exual  Functioning  Inventory  (DSFI)  [105]  does  not  have  a
alidated  French-language  version,  but  assesses  the  quality
f  patient’s  sexual  life.
A  scale  speciﬁc  to  sleep  has  yet  to  be  validated  in  a
rench-language  version  (Table  17).  A  preliminary  validation
hase  will  be  needed  for  it  to  be  employed.
The  only  scale  speciﬁc  to  alcohol  consumption  and
elated  issues  to  have  a  validated  French-language  version
s  the  AUDIT  (Table  18).
There  are  almost  no  data  in  head  and  neck  oncology
oncerning  the  cognitive  impact  of  cancer  and  cancer  treat-
ent  (Table  19):  the  only  speciﬁc  study  found  that  9  out  of
0  patients  showed  cognitive  disorder  [110].  A  speciﬁcity
f  head  and  neck  oncology  is  the  likelihood  of  alcohol-
elated  comorbidity,  with  neuropsychological  consequences
f  varying  severity  that  make  the  question  of  cognitive  func-
ioning  particularly  complex  and  interesting.  There  are  2
ssential  cognitive  assessments  to  perform:  pre-treatment,
o  screen  for  risk  of  non-compliance,  and  post-treatment,
Quality  of  life  tools  in  head  and  neck  oncology  39
Table  8  Scales  speciﬁc  to  mucosities  and  xerostomia.
Scale  Nature  Citations  Misc.
Oral  Mucositis  Weekly  Questionnaire  -
Head  and  Neck  Cancer  (OMWQ-HN)
Speciﬁc  to  mucosities,  not
validated  in  French  [48]
1  12  simple  items
Oral Mucositis  Daily  Questionnaire
(OMDQ)
Speciﬁc  to  mucosities,  not
validated  [49,50]
1  12  simple  items
Oropharyngeal  Mucositis  Quality  Of
Life Scale  (OMQoL)
Speciﬁc  to  mucosities,  not
validated  in  French  [51]
2  4  dimensions:  symptoms,  feeding,
social,  swallowing
Xerostomia  Questionnaire  (XQ) Speciﬁc  to  xerostomia,  not
validated  in  French  [52]
2  8  items  including  4  items  on  dryness
when  eating  or  chewing
Xerostomia  Questionnaire  (XQ) Speciﬁc  to  xerostomia,  not
validated  [53]
2  4  items:  dryness,  oral  route  pain,  loss
of taste,  and  dysphagia
1 dimension:  perceived  QoL  impact
of xerostomia
1 pain  intensity  VAS
Xerostomia  Questionnaire  (XQoL)  Speciﬁc  to  xerostomia,  not
validated  in  French  [54]
2  5  dimensions:  global,  emotional,
functional,  and  physical
1 global  score
Xerostomia Questionnaire  VAS  Speciﬁc  salivary  function,
not  validated  in  French  [55]
1  8  items:  oral  mucosa  dryness,
difﬁculty  in  swallowing  and  speaking,
quantity  of  saliva,  thirst.
Xerostomia-related  Quality  of  Life
scale  (XeQoLs)
Speciﬁc  to  xerostomia,  not
validated  in  French  [56]
1  4  dimensions:  physical,  psychological,
social,  pain/discomfort
1 global  score
Table  9  Scales  speciﬁc  to  swallowing  and  mastication.
Scale  Nature  Citations  Misc.
Deglutition  Handicap  Index
(DHI)  (speciﬁc  scale  not
retrieved  in  literature
search)
Speciﬁc  to  swallowing,  validated
[57—59]
3  dimensions:  emotional,  functional
and  physical
Swallowing  Quality-of-Life
Questionnaire  (SWAL-QOL)
(speciﬁc  scale  not  retrieved
in literature  search)
Speciﬁc  to  swallowing,  validated[60]  10  dimensions:  eating  (burden,
duration,  desire,  food  selection),
communication,  fear,  mental  health,
social  impact,  fatigue  and  sleep
MD Anderson  Dysphagia
Inventory  (MDADI)
Speciﬁc  to  swallowing,  not  validated
in French  [61]
9  4  dimensions:  global,  emotional,
functional,  and  physical
Subjective Chewing  Ability  Speciﬁc,  not  validated  in  French  [62]  2  9  items  on  ability  to  chew  various
foods
Sydney Swallow  Questionnaire
(SSQ)
Speciﬁc  to  swallowing,  not  validated
in French  [63,64]
http://stgcs.med.unsw.edu.au/stgcsweb.
nsf/resources/SSQ/$ﬁle/SSQ.pdf
1  17  items
1 global  score
Dysphagia Handicap  Index
(speciﬁc  scale  not  retrieved
in literature  search)
Speciﬁc  to  swallowing,  not  validated
in French  [65]
3  dimensions:  physical,  emotional
and functional
1  global  score
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Table  10  Scales  speciﬁc  to  functional  assessment  of  shoulder  pathology.
Scale  Nature  Citations  Misc.
Shoulder  Pain  and  Disability  Index
(SPADI)
Speciﬁc,  not  validated  in
French  [66]
1  2  dimensions:  pain  and  disability
Shoulder Disability  Questionnaire  (SDQ)  Speciﬁc  to  pain-related  disability,
not validated  in  French  [67]
1  16  items  for  1  global  score
American Shoulder  and  Elbow  Surgeons
Shoulder
Assessment  (ASESSA)
Speciﬁc  to  functional  assessment
of shoulder  pathology,  not
validated  in  French  [68]
1  5  items  on  pain,  ROM,  force,
stability  and  functional  work
Table  11  Scales  speciﬁc  to  dental  pathology.
Scale  Nature  Citations  Misc.
Geriatric  Oral  Health
Assessment  Index  (GOHAI)
Oro-dental  speciﬁc  index,
validated  [69,70]
1  12  items  for  1  global  score
Oral Health  Impact  Proﬁle
(OHIP)
Oro-dental  speciﬁc  scale,  not
validated  in  French  [71]
2  6  oro-dental  dimensions:  functional
limitation,  physical  pain,  physical  disability,
psychological  discomfort,  psychological
disorder  and  social  handicap
Denture Satisfaction  Dental  speciﬁc  scale,  not
validated  in  French  [72]
2  8  items:  upper  and  lower  dentures,  and
speciﬁc  characteristics  (esthetic,  functional
comfort,  etc.)
Groningen Activity  Restriction
Scale  -  Dentistry  (GARS-D)
Dental  speciﬁc  scale,  not
validated  [73]
2  11  items  on  impact  on  dental  issues  on
social life
Table  12  Scales  speciﬁc  to  feeding.
Scale  Nature  Citations  Misc.
Trial  Speciﬁc  Questionnaire
(TSQ)
Speciﬁc  to  feeding  and  communication,
not  validated  in  French  [75]
1  4  dimensions:  feeding,  language,
social  contact  and  social  anxiety
Willett Food  Frequency
Questionnaire
Speciﬁc  to  foods,  not  validated  in
French  [76]
1  Fruit  and  vegetable  foods
questionnaire
Table  13  Scales  speciﬁc  to  fatigue.
Scale  Nature  Citations  Misc.
Facit-F  Speciﬁc  to  symptoms,  validated
http://www.facit.org/
3  4  dimensions:  physical,  social/family,  emotional,
functional  well-being
13  simple  items  speciﬁc  to  fatigue  intensity
Fact-An Speciﬁc  to  symptoms,  validated
http://www.facit.org/
1  4  dimensions:  physical,  social/family,  emotional,
functional  well-being
20  simple  items  speciﬁc  to  anemia  and  fatigue
Table  14  Scale  speciﬁc  to  oral  pain.
Scale  Nature  Citations  Misc.
University  of  California  San
Francisco  (UCSF)  Oral  Cancer
Pain  Questionnaire
Speciﬁc  to  head  and  neck  cancer,  not
validated  in  French  [78,79]
2  6  items  on  pain:  intensity,  sharpness
and  throbbing  nature,  of  pain  during
and not  during  oral  function
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Table  15  Scales  speciﬁc  to  anxiety,  depression  psychological  impact.
Scale  Nature  Citations  Misc.
Hospital  Anxiety  and
Depression  Scale  (HADS)
Speciﬁc  to  anxiety  and
depression,  validated  [80,81]
21  2  dimensions:  anxiety  and  depression
Beck Depression  Inventory
(BDI)
Speciﬁc  to  depression,
validated  [82]
7  21  items  on  depression  symptom  level
1 total  score
Centre for  Epidemiological
Studies  Depression  Scale
(CES-D)
Speciﬁc  to  depression,
validated  [83,84]
4  1  dimension:  depression
General Health  Questionnaire
(GHQ-30)/
Goldberg  Mental  Health
Survey-12  (GHQ-12)
Speciﬁc  psychiatric
questionnaire,
validated  [85,86]
2  4  dimensions:  depression,  anxiety,
unacceptable  social  behavior,
hypochondria
Montgomery  Asberg  Depression
Rating  Scale  (MADRS)
Speciﬁc  to  depression,
validated  [87,88]
1  10  items:  emotional,  cognitive,  and
physical  symptoms
Perceived Stress  Scale  (PSS)  Speciﬁc  to  stress,  validated
[89]
1  1  score
Geriatric  Depression  Scale  -
Short  Form  (GDS-SF)
Speciﬁc  to  depression,  not
validated  in  French  [90,91]
5  1  dimension
The Illness  Perception
Questionnaire  -  Revised
(IPQ-R)
Speciﬁc,  not  validated  in
French  [92]
3  8  dimensions  measuring  cognitive  and
emotional  representations  of  disease
Mini Mental  Adjustment  to
Cancer  (MINIMAC)
Speciﬁc  to  cancer,  not
validated  in  French  [93]
2  5  dimensions:  ﬁghting  spirit,
helpless/hopeless,  fatalism,  anxious
preoccupation  and  cognitive  avoidance.
Hamilton Rating  Scale  for
Depression  (HRSD)
Speciﬁc  to  depression,  not
validated  in  French  [94]
1  21  items
1 ﬁnal  score
Clinical Global  Impression  -
Severity  (CGI-S)
Speciﬁc  to  depression,  not
validated
1  1  dimension
Hopkins Symptom  Checklist-25  Speciﬁc  to  depression,  not
validated  in  French  [95]
1  25  items  on  depression  and  anxiety
Beck Depression  Inventory  -
Fast  Screen  (BDI-FS)
Speciﬁc  to  depression,  not
validated  in  French  [96]
1  7  items  on  level  of  depression  symptoms
1 total  score
Brief Symptom  Inventory  (BSI)  Speciﬁc  psychiatric  inventory,
not  validated  in  French  [97]
1  3  global  scales  and  9  sub-scales,  including
somatization,  depression,  anxiety
Beliefs about  Medicine
Questionnaire  -  Speciﬁc
Scale  (BMQ-Speciﬁc)
Speciﬁc  to  head  and  neck,  not
validated  in  French  [98]
1  2  dimensions:  necessity  of  treatment  and
worries  about  health  and  possible
side-effects
Distress Inventory  for  Cancer
(DIC2)
Speciﬁc  to  cancer,  not
validated  in  French  [99]
1  7  dimensions:  emotional  distress,  spiritual
distress,  social  distress,  medical  distress,
activity  of  daily  living  and  family-speciﬁc
distress  and  a  total  distress  score
Mental Health  Inventory  (MHI)  Generic  scale,  not  validated  in
French  [100]
1  3  dimensions:  psychological  distress,
psychological  well-being,  global
Eysenck Personality  Inventory  Speciﬁc  to  neurasthenia,  not
validated  in  French  [101,102]
4  3  dimensions:  neurosis,  neurasthenia,
emotional  instability
Life Orientation  Test  -  Revised
(LOT-R)
Speciﬁc,  not  validated  in
French  [103]
2  12  items  on  optimism  and  pessimism
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Table  16  Scale  speciﬁc  to  sexuality.
Scale  Nature  Citations  Misc.
Modiﬁed  Sexual  Adjustment
Questionnaire  for  Head  and
Neck  Cancer  (SAQ)  (speciﬁc
scale  not  retrieved  in
literature  search)
Speciﬁc  to  sexuality  and  head  and
neck cancer,  not  validated  [104]
1  7  items:  sexuality,  sexual  function,
relation/activity
Table  17  Scale  speciﬁc  to  sleep.
Scale  Nature  Citations  Misc.
Medical  Outcomes  Study  -
sleep  (MOS)
Speciﬁc  to  sleep,  not  validated  in
French  [106]
http://gim.med.ucla.edu/FacultyPages/Hays/surveys.htm
2  6  dimensions:  sleep  disorder,  sleep
quality,  somnolence,  snoring,
respiratory  problems,  amount  of
sleep
Table  18  Scales  speciﬁc  to  alcohol  consumption  and  related  issues.
Scale  Nature  Citations  Misc.
Alcohol  Use  Disorder
Identiﬁcation  Test  (AUDIT)
Speciﬁc  to  alcohol,  validated  [107] 5  10  items:  alcoholization  level  and
associated  problems
Michigan Alcoholism  Screening
Test  (MAST)
Speciﬁc  to  alcohol,  not  validated  in
French  [108,109]
2  13  items:  alcohol  consumption
Table  19  Scales  speciﬁc  to  cognitive  functions.
Scale  Nature  Citations  Misc.
Fact-cog  Speciﬁc  to  cancer,  validated
http://www.facit.org/
1 4  subscales:  Perceived  Cognitive
Impairments,  Perceived  Cognitive
Abilities,  Comments  From  Others,
and  impact  of  deﬁcits  on  QoL
Mini-Mental State  Examination
(MMSE)
Speciﬁc  to  cognitive  functions,
validated  [128]
1  30  points
Table  20  Scales  speciﬁc  to  independence.
Scale  Nature  Citations  Misc.
Activities  of  Daily  Living  (ADL)  Speciﬁc  to  independence,
validated  [113]
1  1  global  score  for  body  care,  dressing,
eating,  toileting,
continence,  transferring
Instrumental  Activities  of  Daily
Living  (IADL)
Speciﬁc  to  independence,  validated
[114]
1  1  global  score:  shopping,
housekeeping,  laundering,
accounting,  food  preparation/meds,
telephone/transportation
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Table  21  Scales  speciﬁc  to  support.
Scale  Nature  Citations  Misc.
Brief  COPE  Speciﬁc  to  socialization,
validated  [115,116]
3  14  dimensions:  active  coping,  planning,
suppression  of  competing  activities,
restraint  coping,  seeking  of  instrumental
social  support,  seeking  of  emotional  social
support,  positive  reinterpretation,
acceptance,  denial,  turning  to  religion,
focus  on  and  venting  of  emotions,
behavioral  disengagement,  mental
disengagement
Short-form Social  Support
Questionnaire  (SSQ6)
Speciﬁc  to  social  support,
validated  [117,118]
1  2  dimensions:  number  of  available  social
supports,  satisfaction  with  available
support
Functional  Assessment  of
Chronic  Illness
Therapy-Spiritual
(FACIT-Sp-12)
Speciﬁc  to  spiritual  well-being,
validated
http://www.facit.org/
1  12  items
Cope inventory  Speciﬁc,  not  validated  [119]  5  5  dimensions  of  socialization
Social Provisions  Scale  (SPS)  Speciﬁc,  not  validated  in
French  [120,121]
2  6  dimensions:  attachment,  social
integration,  reassurance  of  worth,  reliable
alliance,  guidance,  and  opportunity  for
nurturance
Work and  Social  Adjustment
(WASA)
Speciﬁc  to  disease  impact,  not
validated  in  French  [122]
1  1  global  score
Openness  to  Discuss  Cancer  in
the  Family  scale  (ODCF
scale)
Speciﬁc,  not  validated  in
French  [123]
1  1  dimension
Utrecht Coping  List  Speciﬁc,  not  validated  in
French  [124]
1  7  dimensions:  active  problem-focusing,
looking  for  distraction,  avoidance,  seeking
social  support,  palliative  reaction  patterns,
expression  of  emotions,  and  optimism
Svebak’s Sense  of  Humor Generic  scale,  not  validated  in 1  1  dimension:  liking  or  loathing  humorous
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to  assess  the  impact  of  chemotherapy.  The  origin  of  dis-
orders  observed  at  end  of  treatment,  however,  is  hard  to
determine:  impact  of  cancer,  of  anti-cancer  treatment,  of
alcohol  consumption,  etc.  Subjective  cognitive  assessment
on  the  FACT-Cog  (Functional  Assessment  of  Cancer  Therapy-
Cognitive  Function)  [111,112]  must  therefore  be  associated
to  a  neuropsychological  assessment  and  take  account  of
alcohol-related  comorbidity.
The  2  scales  speciﬁc  to  independence  have  been
validated  in  their  French-language  versions  and  are  com-
plementary  (Table  20).
The  most  widely  used  support-speciﬁc  scale,  the  Brief
COPE,  has  a  validated  French-language  version  (Table  21).
Qualitative assessmentIn  QoL  assessment,  the  qualitative  is  not  opposed  to  the
quantitative:  they  are  useful  complements.  This  method  of
investigation  is  little  known  to  physicians,  although  seeing
g
o
n
msituations
he  disease  in  the  context  of  the  patient’s  everyday  life
roadens  a  medical  vision  centered  on  physical  data.
The  most  experimental  attitude,  that  of  the  ‘‘participant
bserver’’,  is  time-consuming  but  rich  in  information.
ystematic  ‘‘ﬁeld-work’’  is  the  ethnological  approach
nderpinning  the  theoretic  value  of  research.  The  accu-
ation  of  subjectivity  is  unfounded,  even  if  this  technique
eems  far  removed  from  the  scientiﬁc  requirement  of
uantitative  research.  Lévi-Strauss  and  other  renowned
nthropologists  have  brushed  aside  the  accusation:  rather
han  avoiding  subjectivity,  they  have  made  it  a  ‘‘means  of
bjective  demonstration’’  [126,127]. The  privileged  posi-
ion  we  occupy  in  the  care-giving  relationship  has  a  very
articular  participant-observer  aspect,  as  we  have  both  lit-
rally  and  metaphorically  ‘‘operated  on’’  the  patient’s  body.
hat  is  essential  is  to  constantly  maintain  one’s  ethno-
raphic  identity  so  as  totally  to  respect  the  object  of
ne’s  research.  This  is  a  fairly  novel  attitude  in  head  and
eck  oncology,  shedding  new  light  the  daily  life  of  patients
arked  by  disease  and  treatment  [8].
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onclusion
oL  scales  seem  to  be  the  reference  tools  for  longitudi-
al  follow-up  of  head  and  neck  cancer  patient  cohorts.
hey  reveal  differences  in  perception  between  caregivers
nd  care  receivers  and  in  some  cases  enable  treatment  to
e  optimized.  QoL  research  focuses  the  attention  on  the
ntegration  of  disease  in  everyday  life  and  on  variations
long  different  dimensions  (family  relationships,  work,  etc.)
ccording  to  disease  stage.
The  present  study  provides  a  guide  to  informed  selec-
ion  of  validated  instruments  appropriate  to  head  and  neck
ncology  studies.
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